ADAM33: a novel therapeutic target for asthma
ADAM33: a novel therapeutic target for asthma
The incidence of asthma worldwide is increasing, and the disease has a large unmet clinical need. Despite the availability of anti-inflammatory and bronchodilator medication, there is persisting morbidity and mortality.
New approaches are needed to understand the role that structural changes in the airways (remodelling) play in this process. Studies of the genetic basis of asthma have identified the ADAM33 (a disintegrase and metalloproteinase 33) gene, a novel member of the ADAM family of zinc-dependent metalloproteases, as a risk factor for the development of asthma and bronchial hyperresponsiveness (BHR).
The identification of ADAM33 as a major risk factor involved in the pathogenesis of BHR and airway wall remodelling provides insight into the pathogenesis of asthma and represents a novel therapeutic target
485-494
Powell, Robert M.
884d6594-3f50-4be5-9516-d64b29dad63d
Hamilton, Lynnsey M.
e013c481-745e-41fd-aa9e-ae02967fa44c
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Davies, Donna E.
7de8fdc7-3640-4e3a-aa91-d0e03f990c38
Holloway, John W.
4bbd77e6-c095-445d-a36b-a50a72f6fe1a
2003
Powell, Robert M.
884d6594-3f50-4be5-9516-d64b29dad63d
Hamilton, Lynnsey M.
e013c481-745e-41fd-aa9e-ae02967fa44c
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Davies, Donna E.
7de8fdc7-3640-4e3a-aa91-d0e03f990c38
Holloway, John W.
4bbd77e6-c095-445d-a36b-a50a72f6fe1a
Powell, Robert M., Hamilton, Lynnsey M., Holgate, Stephen T., Davies, Donna E. and Holloway, John W.
(2003)
ADAM33: a novel therapeutic target for asthma.
Expert Opinion on Therapeutic Targets, 7 (4), .
(doi:10.1517/14728222.7.4.485).
Abstract
The incidence of asthma worldwide is increasing, and the disease has a large unmet clinical need. Despite the availability of anti-inflammatory and bronchodilator medication, there is persisting morbidity and mortality.
New approaches are needed to understand the role that structural changes in the airways (remodelling) play in this process. Studies of the genetic basis of asthma have identified the ADAM33 (a disintegrase and metalloproteinase 33) gene, a novel member of the ADAM family of zinc-dependent metalloproteases, as a risk factor for the development of asthma and bronchial hyperresponsiveness (BHR).
The identification of ADAM33 as a major risk factor involved in the pathogenesis of BHR and airway wall remodelling provides insight into the pathogenesis of asthma and represents a novel therapeutic target
This record has no associated files available for download.
More information
Published date: 2003
Identifiers
Local EPrints ID: 27340
URI: http://eprints.soton.ac.uk/id/eprint/27340
ISSN: 1472-8222
PURE UUID: be0db44d-3306-4551-92c5-187673d7e123
Catalogue record
Date deposited: 26 Apr 2006
Last modified: 16 Mar 2024 02:57
Export record
Altmetrics
Contributors
Author:
Robert M. Powell
Author:
Lynnsey M. Hamilton
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
